Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Orion Corporation
Deal Size : $0.6 million
Deal Type : Licensing Agreement
Searchlight Pharma Announces Suvexx® Launch in Europe, Along with Deal Expansion to all E.U. Markets
Details : The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U....
Brand Name : Suvexx
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 15, 2023
Lead Product(s) : Naproxen Sodium,Sumatriptan
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Orion Corporation
Deal Size : $0.6 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
